ENSC
Closed
Ensysce Biosciences Inc
2.24
+0.01 (+0.45%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.23
Day's Range: 2.15 - 2.3
Send
sign up or login to leave a comment!
When Written:
4.86
Ensysce Biosciences Inc is a privately-held biotechnology company that develops and commercializes innovative drug delivery technologies for pain management and addiction treatment. The company was founded in 2008 and is headquartered in San Diego, California.
Ensysce's proprietary drug delivery technologies include the Aversion and DETERx systems, which are designed to deter abuse and reduce the risk of overdose. The Aversion system uses an aversive agent to create an unpleasant experience if the drug is tampered with, while the DETERx system uses a polymer matrix to control the release of the drug over an extended period of time.
Ensysce is focused on developing treatments for opioid addiction and pain management, as well as other therapeutic areas such as oncology and neurology. The company has several products in development, including a buprenorphine implant for opioid addiction and a hydrocodone product for pain management.
Ensysce has received funding from various sources, including the National Institutes of Health (NIH) and private investors. The company has also entered into partnerships with pharmaceutical companies to develop and commercialize its drug delivery technologies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Ensysce's proprietary drug delivery technologies include the Aversion and DETERx systems, which are designed to deter abuse and reduce the risk of overdose. The Aversion system uses an aversive agent to create an unpleasant experience if the drug is tampered with, while the DETERx system uses a polymer matrix to control the release of the drug over an extended period of time.
Ensysce is focused on developing treatments for opioid addiction and pain management, as well as other therapeutic areas such as oncology and neurology. The company has several products in development, including a buprenorphine implant for opioid addiction and a hydrocodone product for pain management.
Ensysce has received funding from various sources, including the National Institutes of Health (NIH) and private investors. The company has also entered into partnerships with pharmaceutical companies to develop and commercialize its drug delivery technologies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








